Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle saline as placebo Clear all
Not yet recruiting Phase 2 Interventional

Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

NCT07756346
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
13 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 30, 2026, 5:02 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

NCT00589953
View directory record Official record
Conditions
Infant, Premature, Erythropoietin, Brain Injury, Intraventricular Hemorrhage, Periventricular Leukomalacia, Neurodevelopmental Outcomes, Randomized Clinical Trial
Interventions
Erythropoietin, Saline placebo
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
Up to 24 Hours
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 30, 2026, 5:02 PM EDT
Recruiting Phase 2Phase 3 Interventional

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

NCT07160205
View directory record Official record
Conditions
Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Interventions
ULSC (1.5 x 10^8 cells/dose), Placebo (no cells)
Biological
Lead sponsor
Restem, LLC.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 30, 2026, 5:02 PM EDT
Completed Not applicable Interventional

Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

NCT01095276
View directory record Official record
Conditions
Atelectasis, Ventilation, Mechanical
Interventions
Pulmozyme (nebulized dornase alpha), Saline
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2010 · Synced Sep 30, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

NCT02061813
View directory record Official record
Conditions
Head Lice
Interventions
Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9%, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 30, 2026, 5:02 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients

NCT07219771
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
PTP-01, Placebo control / saline vehicle
Biological · Other
Lead sponsor
Doron Therapeutics Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • La Mesa, California • West Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 30, 2026, 5:02 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke

NCT03763929
View directory record Official record
Conditions
Stroke, Acute
Interventions
Trans-Sodium Crocetinate, Placebo
Drug · Other
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Sep 30, 2026, 5:02 PM EDT
Recruiting Phase 1 Interventional

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

NCT06504160
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Sep 30, 2026, 5:02 PM EDT
Recruiting Phase 3 Interventional

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244
View directory record Official record
Conditions
Acute Ischemic Stroke, Cerebral Stroke
Interventions
Drug: Normal Saline, Sovateltide
Drug
Lead sponsor
Pharmazz, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
14
States / cities
Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 30, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Lowering Serum Uric Acid to Prevent Acute Kidney Injury

NCT00756964
View directory record Official record
Conditions
Hyperuricemia
Interventions
Rasburicase, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Sep 30, 2026, 5:02 PM EDT
Completed Not applicable Interventional Results available

Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function

NCT02469077
View directory record Official record
Conditions
Chronic Pain
Interventions
6 week aerobic exercise intervention, Placebo, Morphine, naloxone
Behavioral · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 30, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study of ORT247 in Healthy Volunteers

NCT06769620
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
ORT247, Placebo
Drug
Lead sponsor
Orthogonal Neuroscience Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 30, 2026, 5:02 PM EDT
Not yet recruiting Phase 2 Interventional

Visual Instillation of Sphenopalatine-block Intervention for ONgoing Migraine

NCT07764783
View directory record Official record
Conditions
Migraine, Facial Pain or Pressure, Headache
Interventions
Topical solution of 4% lidocaine, Saline 0.9%
Drug
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Sep 30, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

NCT02937558
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Glucagon, Placebo
Drug · Other
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
Up to 12 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Sep 30, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Sep 30, 2026, 5:02 PM EDT
Completed Phase 2 Interventional

Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease

NCT00624351
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Sep 30, 2026, 5:02 PM EDT
Terminated Phase 3 Interventional

Refractory Urge Incontinence and Botox Injections

NCT00373789
View directory record Official record
Conditions
Urinary Incontinence, Detrusor Overactivity, Urinary Urgency, Urge Urinary Incontinence
Interventions
Botulinum Toxin A, bladder detrusor muscle injection, Vehicle saline as placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Sep 30, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

NCT00770146
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Mipomersen sodium, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
62
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Sep 30, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Fluphenazine Hydrochloride for Psoriasis

NCT00929578
View directory record Official record
Conditions
Psoriasis
Interventions
Fluphenazine, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Sep 30, 2026, 5:02 PM EDT